BioSpace News Archive

Arbele, a clinical stage biopharmaceutical company, announces the successful dosing of the first patient in Australia in Phase I Study of ARB202, for the treatment of advanced gastrointestinal cancers patients.

UC Davis, a leading university in molecular imaging that collaborated with United Imaging to develop the world’s first total-body PET/CT scanner, ‘uEXPLORER®,’ recently presented their research on COVID-19 at the 2022 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.

Medicalgorithmics has received FDA approval in the U.S. for its proprietary next generation system in ECG signal analysis called DeepRhytmAI.

Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2022.

DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the second quarter ended June 30, 2022, on Monday, August 15, 2022.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps (“NETs”) in cancer patients with sepsis.

Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic candidates for the treatment of serious and debilitating hematologic diseases, announced today the initiation of BEACON, a phase 2 clinical study of bitopertin in patients with Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP).

Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference.

VieCure, a cancer care company with a market leading artificial intelligence, informatics, and clinical decision support platform, announced a new strategic collaboration with Clarified Precision Medicine which will make precision oncology more accessible for patients and community oncologists.

Exscientia will report financial results for the second quarter ended June 30, 2022, on Wednesday, August 17, 2022 after U.S. market close.